Kevin Harris

Kevin HarrisInterim Chief Financial Officer

Areas of Expertise
  • External Communications
  • M&A
  • Turnarounds
  • Accounting
  • BS, Business Administration, CSUSB

Kevin Harris joined MusclePharm as its Interim Chief Financial Officer on November 1, 2017. Prior to joining MSLP, Mr. Harris served as the Chief Financial Officer of Inpixon (NASDAQ: INPX), a Palo Alto based technology company, from October 2015 until his departure on August 31, 2017.
Mr. Harris had served as the Vice President and Chief Financial Officer of Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient’s response to cancer therapy, from August 2012 to October 2015. Mr. Harris served as Chief Financial Officer and a director of CyberDefender Corporation (NASDAQ: CYDE) from 2009 until August 2012 (and as interim Chief Executive Officer from August 2011 until August 2012). He also served as Chief Operating Officer of Statmon Technologies Corp. (OTCBB: STCA) from 2004 to 2009.

He began his career at KPMG Peat Marwick as a senior auditor. Mr. Harris’s other professional experience includes serving as Head of Production Finance at PolyGram Television, Director of Corporate Financial Planning at Metro-Goldwyn-Mayer Studios and Senior Vice President of Finance at RKO Pictures. Mr. Harris earned a Bachelor of Science in Business Administration from California State University, San Bernardino in 1993, and is a Certified Public Accountant in the State of California.